- Prescribing Advice for GPs - https://www.prescriber.org.uk -

SMC Update - August 2021

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Patiromer sorbitex calcium (Veltassa®) has been accepted for restricted use in the treatment of hyperkalaemia in adults. The restriction limits use to patients with hyperkalaemia (defined as a serum potassium of >6.0mmol/L) with chronic kidney disease (CKD) stage 3b to 5 and/or heart failure, who would otherwise need to down-titrate or discontinue their renin-angiotensin-aldosterone system inhibitor (RAASi) therapy to maintain a clinically acceptable serum potassium level (normokalaemia).

Inclisiran (Leqvio®) has been accepted for restricted use in the treatment of adults with primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia, as an adjunct to diet:

The restriction limits use to patients at high cardiovascular risk as follows:

It should also be noted that this recommendation applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower. It is therefore expected that this medication would be supplied through secondary care.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.